Stratified analysis suggested that the 19-EMT-related signature was still a clinically and statistically significant prognostic model in patients in the different sex, age, tumor site, pathological T stage, pathological N stage, chemotherapy status, TP53 status, KRAS status, and BRAF status subgroups (Figure 4). This evidence concerns the gene TP53 and neoplasm.